Pre and Post-arterial Recanalization Imaging of Central Retinal Artery Occlusions (CRAO) (I-RECANAL)

Central retinal artery occlusions (CRAO) are the equivalent of an ischemic stroke at the retinal level. They share the same risk factors and common pathology. The diagnosis of a CRAO is clinically based on the sudden occurrence of a decrease in deep visual acuity with fundamentally signs of reactive ischemia.

Small studies have highlighted the value of cerebral MRI (Magnetic Resonance Imaging) in CRAO with almost 25% of ischemic strokes found on diffusion sequences and the demonstration of a correlation between anomalies in diffusion sequence and the probability of a pathology with a high risk of recurrence (carotid stenosis or emboligenic cardiopathy). But there are usually few radiological signs that allow a direct positive diagnosis of CRAO, an etiologic diagnosis or a prognosis. This descriptive study will focus on CRAO at the diagnostic and post-treatment phases in the short and medium term, in order to (i) identify imaging etiologic signs of CRAO with specific sequences from a 3 Tesla MRI, (ii) identify positive diagnostic signs of CRAO with the same specific sequences, (iii) correlate these signs with the visual prognosis one month after the CRAO.

Study Overview

• Status: Completed
• Conditions: Magnetic Resonance Imaging; Diagnosis; Prognosis; Retinal Artery Occlusion; Etiology
• Intervention / Treatment: Device: Additional MRI sequences

• Study Type: Observational
• Enrollment (Actual): 63

Contacts and Locations

Study Locations

• France
  • Paris, France
    • Fondation Ophtalmologique A. De Rothschild

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No

• Sampling Method: Probability Sample

Study Population

Adult patients hospitalized for CRAO ≤ 48 hours.

Description

Inclusion Criteria:

• 18 years of age or older
• CRAO (onset of symptoms ≤ 48 hours)
• Consent to participate in the study

Exclusion Criteria:

- Contraindications to 3 Tesla MRI

Study Plan

How is the study designed?

Design Details

• Observational Models: Case-Only
• Time Perspectives: Prospective

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Contrast enhancement of the ophthalmic artery	Binary variable (yes/no)	Baseline
Presence of a thrombus	Binary variable (yes/no)	Baseline
Presence of an arterial stenosis of the supra aortic trunks	Binary variable (yes/no)	Baseline
Hypersignal of the ophthalmic artery in diffusion	Binary variable (yes/no)	Baseline
Restriction of the apparent diffusion coefficient (ADC) at the optic nerve level and at the papilla level	Binary variable (yes/no)	Baseline

Collaborators and Investigators

• Sponsor: Fondation Ophtalmologique Adolphe de Rothschild

Study record dates

Study Major Dates

• Study Start (Actual): December 13, 2017
• Primary Completion (Actual): October 24, 2023
• Study Completion (Actual): January 24, 2024

Study Registration Dates

• First Submitted: September 25, 2017
• First Submitted That Met QC Criteria: October 13, 2017
• First Posted (Actual): October 18, 2017

Study Record Updates

• Last Update Posted (Actual): January 5, 2026
• Last Update Submitted That Met QC Criteria: December 30, 2025
• Last Verified: December 1, 2025

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Vascular Diseases; Cardiovascular Diseases; Pathologic Processes; Eye Diseases; Arterial Occlusive Diseases; Retinal Diseases; Pathological Conditions, Signs and Symptoms; Disease; Retinal Artery Occlusion
• Other Study ID Numbers: ALR_2017_17

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No